Home  |  Contact

UniProtKB/Swiss-Prot P60891: Variant p.Asn114Ser

Ribose-phosphate pyrophosphokinase 1
Gene: PRPS1
Variant information

Variant position:  114
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Asparagine (N) to Serine (S) at position 114 (N114S, p.Asn114Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (N) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In PRPS1 superactivity.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  114
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  318
The length of the canonical sequence.

Location on the sequence:   YARQDKKDKSRAPISAKLVA  N MLSVAGADHIITMDLHASQI
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YARQDKKDKSRAPISAKLVANMLSVAGADHIITMDLHASQI

Mouse                         YARQDKKDKSRAPISAKLVANMLSVAGADHIITMDLHASQI

Rat                           YARQDKKDKSRAPISAKLVANMLSVAGADHIITMDLHASQI

Bovine                        YARQDKKDKSRAPISAKLVANMLSVAGADHIITMDLHASQI

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 318 Ribose-phosphate pyrophosphokinase 1
Metal binding 128 – 128 Magnesium
Metal binding 130 – 130 Magnesium
Binding site 130 – 130 ATP
Mutagenesis 132 – 132 S -> A. Reduces catalytic activity.
Mutagenesis 132 – 132 S -> F. No effect on catalytic activity.
Helix 108 – 119


Literature citations

Identification of distinct PRPS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity.
Roessler B.J.; Palella T.D.; Heidler S.; Becker M.A.;
Cited for: VARIANTS PRPS1 SUPERACTIVITY SER-114 AND HIS-183;

The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity.
Becker M.A.; Smith P.R.; Taylor W.; Mustafi R.; Switzer R.L.;
J. Clin. Invest. 96:2133-2141(1995)
Cited for: VARIANTS PRPS1 SUPERACTIVITY HIS-52; SER-114; ILE-129; HIS-183; VAL-190 AND GLN-193;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.